Advertisement

Research on Chemical Intermediates

, Volume 44, Issue 11, pp 6479–6487 | Cite as

Non-coordination planer cis-and trans-configuration of cis-[Pt(II)(mixed-NH3/RNH2)(3-OH-cyclobutane-1,1-dicarboxylate)]: separation, characterization, and anticancer activity

  • Jing Jiang
  • Jie Qiu
  • Liguang Lou
  • Anli Gao
  • Shuqian Hou
  • Weiping Liu
Article
  • 30 Downloads

Abstract

Two isomers of cis-[Pt(II)(mixed-NH3/RNH2)(3-OH-cyclobutane-1,1-dicarboxylate)] (R = cycopentyl, cyclohexyl) were separated, structurally characterized and tested for their anticancer activity. X-ray structural analysis revealed that this isomerism originates from two opposite spatial orientations of the hydroxyl group on the cyclobutane ring in relation to the coordinated NH3, resulting in cis- and trans-configurations. The two isomers have approximately equal anticancer activity, probably due to a relatively long distance between the hydroxyl group and the Pt(II) coordination plane. Therefore, the separation of such isomers is not recommended during drug development.

Keywords

Platinum(II) complexes Anticancer activity 3-OH-cyclobutane-1,1-dicarboxylate Mixed-NH3/RNH2 Non-coordination planer cis-/trans-isomerism 

Notes

Acknowledgements

This work was supported by the Natural Science Foundation of China (Grant Number 21661018); Yunnan Provincial R&D Project of China (Grant Numbers 2014BC010 and 2017ZF010).

Supplementary material

11164_2018_3503_MOESM1_ESM.docx (487 kb)
Supplementary material 1 (DOCX 487 kb)

References

  1. 1.
    X. Han, J. Sun, Y. Wang, Z. He, Med. Res. Rev. 35, 1268 (2015)CrossRefGoogle Scholar
  2. 2.
    X. Chen, Y. Wu, H. Dong, C.Y. Zhang, Y. Zhang, Curr. Mol. Med. 13, 1603 (2013)CrossRefGoogle Scholar
  3. 3.
    J.W. Nial, W. Shonag, E.C. Gemma, O. Rabbab, Dalton Trans. 39, 8113 (2010)CrossRefGoogle Scholar
  4. 4.
    T.C. Johnstone, K. Suntharalingam, S.J. Lippard, Chem. Rev. 116, 3436 (2016)CrossRefGoogle Scholar
  5. 5.
    C. Barnard, Johns. Matthey Technol. Rev. 61, 52 (2017)CrossRefGoogle Scholar
  6. 6.
    M. Drees, W.M. Dengler, H.R. Hendriks, L.R. Kelland, H.H. Fiebig, Eur. J. Cancer 31, 356 (1995)CrossRefGoogle Scholar
  7. 7.
    M.A. Jakupec, M. Galanski, B.K. Keppler, Biochem. Pharmacol. 146, 1 (2003)Google Scholar
  8. 8.
    W. Liu, J. Su, J. Jiang, X. Li, Q. Ye, H. Zhou, J. Chen, Y. Li, Nat. Sci. Rep. 3, 2464 (2013)CrossRefGoogle Scholar
  9. 9.
    S.A. Sadeek, W.H. El-Shwiniy, J. Iran. Chem. Soc. 14, 1711 (2017)CrossRefGoogle Scholar
  10. 10.
    S.A. Sadeek, M. Sherif, A.E. El-Hamid, W.H. El-Shwiniy, Res. Chem. Intermed. 42, 3183 (2016)CrossRefGoogle Scholar
  11. 11.
    H.W. El-Shwiniy, A.Z. Wael, Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 199, 290 (2018)CrossRefGoogle Scholar
  12. 12.
    G.M. Sheldrick, Acta Crystallogr. A 64, 112 (2008)CrossRefGoogle Scholar
  13. 13.
    W. Liu, Q. Ye, J. Jiang, L. Lou, Y. Xu, C. Xie, M. Xie, ChemMedChem 8, 1465 (2013)CrossRefGoogle Scholar
  14. 14.
    W. Liu, X. Chen, Q. Ye, S. Hou, L. Lou, C. XiSe, Platin. Met. Rev. 56, 248 (2012)CrossRefGoogle Scholar
  15. 15.
    W. Liu, X. Chen, Q. Ye, Y. Xu, C. Xie, L. Lou, Inorg. Chem. 50, 5324 (2011)CrossRefGoogle Scholar
  16. 16.
    J. Zhao, S. Gou, Y. Sun, R. Yin, Z. Wang, Chem. Eur. J. 18, 14276 (2012)CrossRefGoogle Scholar
  17. 17.
    J. Zhao, S. Gou, Y. Sun, L. Fang, Z. Wang, Inorg. Chem. 51, 10317 (2012)CrossRefGoogle Scholar
  18. 18.
    L. Kelland, Nat. Rev. Cancer 7, 573 (2007)CrossRefGoogle Scholar
  19. 19.
    S. Dilruba, G.V. Kalayda, Cancer Chemother. Pharmacol. 77, 1103 (2016)CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  1. 1.State Key Laboratory for Platinum Group MetalsKunming Institute of Precious MetalsKunmingPeople’s Republic of China
  2. 2.Lincan Maternal and Child Health Care HospitalKaiyuanPeople’s Republic of China
  3. 3.Shanghai Institute of Materia MedicaChinese Academy of ScienceShanghaiPeople’s Republic of China

Personalised recommendations